Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying ...

The Arcturus subvariant stems from the Omicron strain of Covid-19 and is known as XBB.1.16 since it descends from the recombinant variant XBB, which combines two sublineages of Omicron BA.2.

Meanwhile Arcturus, a San Diego biotech working with messenger RNA (mRNA) therapies said it is working with Duke-NUS Medical School (Duke-NUS) to develop a coronavirus vaccine for Singapore.

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive has been approved for marketing in the EU, becoming the first based on self-amplifying mRNA (sa-mRNA) to clear that threshold. While ...

The Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing ("Rospotrebnadzor") sees a risk of the increased incidence of infections with the Arcturus COVID-19 ...

‘Arcturus’ XBB.1.16: CDC tracker and map show where the latest COVID-19 variant is spreading A new variant of COVID-19, unofficially nicknamed “Arcturus,” is spreading across America and ...

Numbers and graphics on this page will continue to update automatically but may become out of date as public health agencies wind down reporting of various COVID-19 metrics. This page tracks the ...

Stay updated on market trends for ARCT. Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL and Arcturus Therapeutics report that their ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...